-
Cyclosporin A: From Mechanism to Translation
2026-09-28
Cyclosporin A, also known as cyclosporine, is best understood as a context-dependent cyclophilin inhibitor rather than a generic immunosuppressant. This thought-leadership guide connects calcineurin-NFAT signaling, mitochondrial injury, apoptosis modulation, formulation strategy, and translational model design while defining practical limits for autoimmune disorder research, retinal ischemic injury models, and viral entry inhibition studies.
-
Machine Learning for Senolytic Discovery
2026-09-28
A machine-learning screen trained on published compound data identified ginkgetin, periplocin, and oleandrin as senolytic candidates, which the authors validated in human cell models of senescence. The study shows how computational prioritization can make early drug discovery more economical while emphasizing that cell-type selectivity and experimental validation remain essential.
-
RBMS1 Loss Sensitizes TNBC to Immunotherapy
2026-09-27
The study identifies the RNA-binding protein RBMS1 as a regulator of PD-L1 stability in triple-negative breast cancer. RBMS1 depletion destabilizes B4GALT1 mRNA, reduces PD-L1 glycosylation, and promotes PD-L1 degradation, with preclinical evidence that this can strengthen cytotoxic T-cell activity and complement immunotherapy approaches.
-
Biotin (Vitamin B7) for Antiviral Assay Design
2026-09-26
Biotin (Vitamin B7) is best understood not only as a metabolic cofactor but also as an affinity handle whose use must be separated from biological signaling. This article applies that distinction to shrimp STING research, showing how to plan informative labeling and capture assays without mistaking a detection tool for an antiviral mechanism.
-
Aumolertinib Plus Radiation for EGFRm Brain Metastases
2026-09-25
A preclinical study tested aumolertinib with ionizing radiation in EGFR-mutant NSCLC brain-metastasis models, combining tumor-response experiments with measurements of drug levels in brain tissue and blood. The findings support further study of the combination, while leaving important questions about treatment scheduling, mechanism, and clinical benefit unresolved.
-
Superoxide Dismutase Activity Assay: Practical Guide
2026-09-25
Measure functional SOD activity with a rapid, 450 nm colorimetric workflow—and interpret it separately from direct hydrogen peroxide measurements. This guide covers sample setup, assay controls, practical troubleshooting, and a key probe-specific limitation reported in mitochondrial ROS research.
-
BMN 673: A Practical PARP1/2 Research Workflow
2026-09-24
Build a stronger PARP-inhibitor study by pairing BMN 673 (Talazoparib) dose–response testing with DNA-repair and PARP-retention readouts. This workflow connects potent PARP1/2 inhibition to BRCA2–RAD51 biology while emphasizing controls that distinguish target engagement from cell-line-specific effects.
-
CGK733 for Ferroptosis Assay Workflows
2026-09-24
Use CGK733 as an exploratory perturbation in carefully controlled glioblastoma iron-and-ferroptosis experiments—not as an established ferroptosis reagent. A staged workflow separates compound effects from the TP53–FTH biology reported in the reference study and highlights the controls needed to interpret either result.
-
Nifedipine (BAY-a-1040) Research Workflows
2026-09-24
Use Nifedipine (BAY-a-1040) to probe L-type calcium-channel-dependent responses, then pair calcium readouts with viability, iron-handling, or CYP assays to separate cellular effects. A rat PXR study offers a useful model for designing metabolic-function measurements—but does not test nifedipine or establish it as a PXR modulator.
-
LG 101506: RXR Modulator Workflow for TNBC
2026-09-23
Use LG 101506 as a reversible chemical probe to connect RXR biology with PD-L1 regulation in triple-negative breast cancer models. This workflow pairs dose- and time-resolved RXR modulation with RBMS1 perturbation, glycosylation analysis, and immune-cell assays while clearly separating established findings from testable extensions.
-
LG 101506: RXR Modulator Workflow Guide
2026-09-22
Build reproducible RXR signaling experiments with LG 101506 using staged dose–time testing, orthogonal transcriptional and protein readouts, and practical controls. The guide also shows how to use the compound to formulate, but not overstate, hypotheses connecting nuclear receptor signaling with immune-checkpoint biology in triple-negative breast cancer.
-
Cyclic di-GMP: From Biofilm Timing to STING
2026-09-22
Cyclic di-GMP is an intracellular second messenger that links early biofilm persistence mechanisms with STING-focused immune modulation research. This article presents an assay-centered framework for separating bacterial antitoxin biology from mammalian STING agonism and choosing more informative experimental controls.
-
D-Luciferin: From Brain Tumor Signal to Strategy
2026-09-21
A mechanistic and translational framework for using D-Luciferin potassium salt in longitudinal tumor studies, with particular emphasis on EGFR-mutant NSCLC brain metastasis models, assay design, and evidence-based interpretation.
-
HABA: Avidin–Biotin Assay Reagent
2026-09-21
HABA, or 4-hydroxyazobenzene-2-carboxylic acid, is a chromogenic ligand for avidin and streptavidin binding assays. Its absorbance response supports biotin accessibility measurements, but it does not replace particle sizing, surface-charge analysis, or HPLC-based drug-release testing.
-
Recombinant Human EGF in MYC-TNBC Assays
2026-09-20
Use recombinant human EGF as a controlled EGFR stimulus, assay benchmark, and culture-variable when investigating proliferation or drug sensitivity in MYC-driven triple-negative breast cancer models. This workflow connects product-quality controls with the EphA2 synthetic-lethality findings reported in a recent chemogenetic screen without implying that EGF itself is an EphA2 inhibitor.